


Rewrite page 2, section 0009, as follows:

[0009] The present invention provides a pharmaceutical composition comprising a compound of formula (1) in a selected crystalline form:



1

together with a pharmaceutically acceptable carrier or excipient, wherein the selected crystalline form is composed of polymorphic form A, substantially free of undesired polymorphs. By “substantially free” is meant that little or no undesired polymorphs are detectable by powder X-ray diffractometry (PXRD). Typically, the polymorphic purity is greater than 90% (defined by peak heights in the powder x-ray diffraction trace). Preferably, the desired crystalline form of the invention is at least about 95% of the polymorphic form A (Fig. 6) as measured by relative peak heights in the region of 9° 2-theta.

REMARKS

Two occurrences of formula 1 had typographical errors, which have been corrected. Support for the correction is found in all the other occurrences of formula 1, and the synthetic method described on page 5. No new matter has been added.